Modera Wealth Management LLC Sells 17,520 Shares of Novo Nordisk A/S $NVO

Modera Wealth Management LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 288,276 shares of the company’s stock after selling 17,520 shares during the period. Modera Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $10,929,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Root Financial Partners LLC bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $32,000. Continuum Advisory LLC acquired a new position in Novo Nordisk A/S during the second quarter valued at approximately $38,000. Latitude Advisors LLC acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $38,000. Finally, Markowski Investments bought a new stake in Novo Nordisk A/S during the second quarter worth $43,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 2.1%

Shares of NVO stock opened at $39.96 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock’s fifty day simple moving average is $41.23 and its 200 day simple moving average is $44.34. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $178.42 billion, a P/E ratio of 9.74, a P/E/G ratio of 1.33 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The firm had revenue of $11.98 billion during the quarter. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a $0.5786 dividend. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Jefferies Financial Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Cfra downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price for the company. in a research note on Tuesday, September 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $59.44.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s new 2030 targets emphasize pipeline expansion, broader treatment offerings and the goal of serving more patients. The strategy could help reduce the company’s dependence on its current GLP-1 franchise and support a long-term recovery. Novo Nordisk Sets New 2030 Goals As GLP-1 Competition Builds
• Positive Sentiment: The global weight-loss market is forecast to expand substantially through 2036, providing a large long-term opportunity for Novo Nordisk as demand grows for GLP-1 drugs, oral therapies, telehealth and direct-to-patient distribution. Global Weight Loss Market Size, Share, Trends and Forecast
• Positive Sentiment: Erste Group Bank maintained a bullish outlook for Novo Nordisk’s fiscal 2026 earnings, while recent commentary argues that the shares’ sharp multi-year decline has left the company looking inexpensive relative to its earnings potential. Erste Group Bank Has Bullish Outlook for NVO FY2026 Earnings
• Neutral Sentiment: Novo Nordisk is receiving elevated investor attention, but trending-stock coverage primarily highlights factors to monitor rather than a new fundamental catalyst. What to Know Beyond Why Novo Nordisk Is a Trending Stock
• Negative Sentiment: Eli Lilly’s strong results and raised outlook reinforce its lead in obesity drugs, underscoring the competitive pressure facing Novo Nordisk. Investors may require stronger pipeline execution and evidence that the 2030 plan can offset slowing momentum in current GLP-1 products. Eli Lilly Jumps as Strong Quarter Lifts Revenue Outlook

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.